Skip to main navigation
Harrow Health

> Main Menu

About Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers
Contact
Investors Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

> Main Menu

About
Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers Contact
Investors
Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

Press Releases

May 17, 2023
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
May 11, 2023
Harrow Announces First Quarter 2023 Financial Results
May 4, 2023
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
May 2, 2023
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
April 27, 2023
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
March 28, 2023
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
March 23, 2023
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
March 13, 2023
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
March 6, 2023
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
March 2, 2023
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 14
Harrow Health

Address

102 Woodmont Blvd., Suite 610
Nashville, TN 37205

Phone

(615) 733 4730
(615) 733 4737 (Investor Relations)

Social

LinkedIn

© 2023 Harrow Health, Inc.

> Footer

Privacy Policy Cookie Notice